Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Total Non-Current Liabilities of $5.3 million for Q1 2026, up 29.08% year-over-year from $4.1 million in Q1 2025, and up 29.08% quarter-over-quarter from $4.1 million in Q1 2025.
Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Total Non-Current Liabilities for 3 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.86 Mn |
| Mar 31, 2026 | 5.31 Mn |
| Mar 31, 2025 | 4.12 Mn |
| Mar 31, 2024 | 4.29 Mn |